11/4/2026

speaker
Operator
Conference Call Operator

Hello, and welcome to Veer Biotechnology's 3rd Quarter 2026 Financial Results and Corporate Update Conference Call. As a reminder, this call is being recorded. At this time, all participants are in a listen-only mode. After the speaker's prepared remarks, there will be a question-and-answer session. I will now turn the call over to Kiki Patel, Head of Investor Relations. You may begin, Kiki.

speaker
Kiki Patel
Head of Investor Relations, Vir Biotechnology

Thank you, Operator, and welcome, everyone. Earlier today, we issued a press release reporting our third quarter 2026 financial results and corporate update. Before we begin, I'd like to remind everyone that some of the statements we are making today are forward-looking statements under applicable securities laws. Forward-looking statements include but are not limited to statements regarding the therapeutic and commercial potential of our clinical and preclinical programs, our development plans and timelines, Our collaborations with other companies, our cash runway, and capital allocation priorities, and as otherwise described in the legal disclaimers accompanying our public presentations. These forward-looking statements involve substantial risks and uncertainties, which are described in our reports filed with the Securities and Exchange Commission, including our Forms 10-K, 10-Q, and 8-K, and could cause future results, performance, or achievements to differ significantly from those expressed or implied by such forward-looking statements. Joining me on today's call from Veer Biotechnology are Dr. Marianne De Backer, our President and Chief Executive Officer, and Aziz Sawaf, our Chief Financial Officer. The agenda for our call today is as follows. Next, Aziz will review the financial terms of our recent collaboration with Gilead and provide a summary of our third quarter 2026 financial results. And finally, Marianne will close the call and we'll open the line for Q&A. With that, I'll now turn the call over to Marianne.

speaker
Marianne De Backer
President and Chief Executive Officer, Vir Biotechnology

Thank you, Kiki. Good afternoon, everyone. And thank you for joining us for FearBioTechnology's third quarter 2026 financial results conference call. We are entering a pivotal period for Virbio, with the potential to transform hepatitis delta treatment while building a differentiated oncology franchise. Today, I will highlight significant progress across both those areas and why we believe Virbio is well positioned for meaningful value creation ahead. First, we've expanded our leadership team with the addition of Aziz Sawaf as Chief Financial Officer and Dr. David Liu as Chief Medical Officer. Both bring more than 20 years of experience in their respective fields, further bolstering our capabilities as we enter an important period for Veerbio. With our leadership team strengthened, we are well positioned to execute against the significant opportunities and catalysts ahead. Second, our Hepatitis Delta program continues to advance through Phase 3 development. We expect to report top-line data from Eclipse 1 this quarter, followed by top-line data from Eclipse 2 and Eclipse 3 in the first quarter of 2027. We will also present expanded 96-week Phase 2 solstice results in an oral presentation at AASLD this weekend. Third, we have made meaningful progress across our oncology portfolio. Astellas recently announced that VIR5500 achieved proof of concept, reinforcing the scientific rationale for advancing the program into late-stage development. In addition, we are pleased to share that the FDA granted fast-track designation to VIR5500 for the treatment of late-line metastatic castration-resistant prostate cancer. And finally, our recent research collaboration with Gilead underscores the potential of our ProX10 platform and highlights the strength of our integrated AI-enabled capabilities in T-cell engager discovery and optimization. This collaboration represents the second major external validation of the ProX10 masking technology in the last eight months, following our partnership with Astellas on VR5500 in February. Overall, these achievements position us well to execute on our strategic priorities and deliver against the important catalysts ahead. Now starting with our Hepatitis Delta program. Chronic Hepatitis Delta remains one of the most severe and underserved forms of viral liver disease. October was Liver Cancer Awareness Month, and the World Hepatitis Alliance has focused on amplifying the message that hepatitis elimination is liver cancer prevention. Hepatitis Delta is associated with a two to six-fold higher risk of liver cancer compared to hepatitis B alone and was classified as carcinogenic by the World Health Organization's International Agency for Research on Cancer last year. Thank you very much. Hepatologists and treating physicians believe that achieving complete viral elimination to where the virus is undetectable, defined by HDV, RNA, target not detected, or TND, represents an important next frontier in hepatitis delta care, representing deeper disease control and potential clinical benefit for patients. Building on the encouraging T&D results observed in our Phase II solstice trial, the ECLIPSE program is designed to determine whether this approach can consistently deliver profound viral suppression across key populations. ECLIPSE I is designed to provide the first Phase III assessment of the proportion of patients who can achieve undetectable HDV RNA after 48 weeks of treatment with our combination regimen of Elapseron and Tobevibart. The trial has enrolled approximately 120 participants, randomized 2 to 1, to monthly subcutaneous dosing of our combination regimen versus deferred treatment in treatment-naive patients with chronic hepatitis delta. The primary endpoint is a composite of HDV RNA TND together with ALT normalization at week 48. Eclipse 2 has enrolled approximately 150 patients who are being randomized 2 to 1, evaluating the switch to our combination therapy in patients who have an inadequate response to belavetide. The primary endpoint for the trial is undetectable virus as defined by HDV, RNA, TND at week 24. The pace of enrollment we observed in Europe for this trial reflects an important unmet need in patients previously treated with bulevertide. ECLIPSE III is our pivotal head-to-head trial against bulevertide in treatment-naive patients. We have enrolled approximately 100 patients, randomized 2 to 1, to our combination therapy versus Belevertide. The primary endpoint for the trial is undetectable virus, as defined by HDV, RNA, TND at week 48. Together, Eclipse 1, 2, and 3 are expected to provide a comprehensive data package, generating data in treatment-naive patients, Patients switching from bulevertide and patients enrolled in a head-to-head comparison against bulevertide. As bulevertide utilization grows, physicians will need evidence-based guidance on how best to manage patients who do not achieve adequate viral suppression or who require an alternative treatment approach. To our knowledge, no other late-stage HDV development program is expected to include comparable belevertide switch or head-to-head data in its regulatory submission package, potentially providing a uniquely comprehensive evidence base for physicians, payers, and regulators. Collectively, these studies are designed to position our program at the very forefront of the evolving hepatitis delta treatment landscape. and ultimately improve outcomes for patients living with this devastating disease. Turning now to oncology. PURE5500 is our ProX10 dual-masked PSMA-targeted T-cell engager, which we are advancing in a global co-development and co-commercialization collaboration with Astellas for prostate cancer. Astellas already shared on its earnings call yesterday that FEAR 5500 has achieved proof of concept, reinforcing the scientific rationale for advancing the program into registrational trials. This assessment reflects the totality of the clinical, safety, pharmacology, and biomarker data generated to date and supports continued investment in the registrational planning and execution. We also recently announced that the FDA granted fast-track designation to VR5500 for the treatment of late-line metastatic castration-resistant prostate cancer, or MCRPC, underscoring VR5500's potential to address a significant unmet need in patients who have limited treatment options. Both of these milestones highlight the strong progress we have made with our partner Astellas as we advance the program PURE5500 is currently being evaluated in a Phase I trial as both a monotherapy and combination therapy across six dose expansion cohorts. Indications include taxane-naive MCRPC, radioligand therapy-naive MCRPC, radioligand therapy-exposed MCRPC, and metastatic hormone-sensitive prostate cancer. These expansion studies are designed to inform the next phase of development with the goal of initiating multiple phase 3 studies spanning both early-line and late-line settings in 2027. In parallel, we are focused on advancing manufacturing readiness in collaboration with Astellas. Thank you for joining us. with dose escalation and signal finding components both as monotherapy and in combination with pembrolizumab. The trial has enrolled patients with a variety of HER2-expressing cancers. During our last update on the program, we shared encouraging antitumor activity and a generally well-tolerated safety profile. Thank you very much. As a result, the study remains ongoing and the dataset is not yet complete. In parallel, dose escalation and optimization of VIR5818 in combination with pembrolizumab is ongoing. We anticipate presenting a meaningful update on VIR5818 at a future scientific conference. Finally, PURE5525, our EGFR-targeted T-cell engager, continues to progress through dose escalation in both monotherapy and combination therapy with pembrolizumab across lung cancer, colorectal cancer, head and neck squamous cell carcinoma, and cutaneous squamous cell carcinoma. Looking ahead, our preclinical immuno-oncology pipeline is fueling a growing oncology portfolio. We are in a fortunate position where the breadth of opportunities generated by our scientific platform exceeds what we can advance independently, allowing us to be strategic about which programs we progress ourselves. Thank you very much. Thank you very much. Thank you very much. Providing further external validation of the ProX10 platform and the potential to deliver T-cell engagers with an improved safety profile. This preclinical multi-program collaboration leverages Virebio's integrated expertise in T-cell engager discovery and protein engineering. Our proprietary DAISY AI platform for rapid multi-parameter optimization of high-quality T-cell engagers. and the ProX10 masking technology to develop next-generation T-cell engagers across multiple solid tumor targets. Under the agreement with Gilead, FearBio will be responsible for the discovery, design and optimization of three ProX10 mask T-cell engager development candidates with the potential to address multiple solid tumor indications with significant unmet medical need. Gilead will have the exclusive right to advance candidates generated through the collaboration and will be responsible for subsequent development, manufacturing and commercialization. With that, I'll now hand the call over to Aziz, who will walk through the financial terms of our Gilead collaboration and our third quarter financial results.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API

Investor presentation